Multivariable analysis for UCB HCT vs haploidentical HCT, 2013-2017
| Covariate . | No. . | HR . | 95% Confidence interval . | P . |
|---|---|---|---|---|
| OS | ||||
| UCB HCT vs haploidentical HCT (mo) | ||||
| ≤18 | 1.93 | 1.45-2.56 | <.001 | |
| >18 | 0.68 | 0.38-1.21 | .19 | |
| Remission status | ||||
| CR1 | 481 | Reference | ||
| CR2+ | 217 | 1.62 | 1.27-2.07 | <.001 |
| Karnofsky performance status (%) | ||||
| <90 | 259 | Reference | ||
| ≥90 | 429 | 0.81 | 0.64-1.04 | .10 |
| Conditioning regimen | ||||
| MAC-TBI | 380 | Reference | ||
| MAC-chemotherapy | 74 | 2.14 | 1.45-3.14 | <.001 |
| RIC/NMA | 243 | 1.22 | 0.93-1.59 | .15 |
| LFS | ||||
| UCB HCT vs haploidentical HCT (mo) | ||||
| ≤18 | 1.40 | 1.09-1.79 | .007 | |
| >18 | 0.58 | 0.31-1.07 | .08 | |
| Remission status | ||||
| CR1 | 469 | Reference | ||
| CR2+ | 203 | 1.59 | 1.27-1.99 | <.001 |
| Race/ethnicity | ||||
| White Hispanic | 144 | Reference | ||
| White non-Hispanic | 310 | 0.86 | 0.65-1.13 | .27 |
| Black | 83 | 1.33 | 0.93-1.89 | .12 |
| Asian | 41 | 0.55 | 0.31-0.97 | .04 |
| Other/not specified | 94 | 0.94 | 0.65-1.36 | .74 |
| Conditioning regimen | ||||
| MAC-TBI | 364 | Reference | ||
| MAC-chemotherapy | 72 | 1.77 | 1.23-2.55 | .002 |
| RIC/NMA | 235 | 1.51 | 1.19-1.91 | <.001 |
| NRM | ||||
| Main effect | ||||
| Haploidentical HCT | 381 | Reference | ||
| UCB HCT | 291 | 2.08 | 1.45-2.99 | <.001 |
| Karnofsky performance status (%) | ||||
| <90 | 247 | Reference | ||
| ≥90 | 416 | 0.65 | 0.46-0.90 | .01 |
| Conditioning regimen | ||||
| MAC-TBI | 364 | Reference | ||
| MAC-chemotherapy | 72 | 1.96 | 1.16-3.32 | .01 |
| RIC/NMA | 235 | 0.88 | 0.59-1.29 | .51 |
| Relapse | ||||
| Main effect | ||||
| Haploidentical HCT | 381 | Reference | ||
| UCB HCT | 291 | 0.83 | 0.60-1.13 | .23 |
| Remission status | ||||
| CR1 | 469 | Reference | ||
| CR2+ | 203 | 1.88 | 1.40-2.53 | <.001 |
| Race/ethnicity | ||||
| White Hispanic | 144 | Reference | ||
| White non-Hispanic | 310 | 0.99 | 0.68-1.45 | .98 |
| Black | 83 | 1.51 | 0.95-2.39 | .08 |
| Asian | 41 | 0.55 | 0.26-1.19 | .13 |
| Other/not specified | 94 | 0.73 | 0.43-1.25 | .25 |
| Conditioning regimen | ||||
| MAC-TBI | 364 | Reference | ||
| MAC-chemotherapy | 72 | 1.64 | 0.99-2.71 | .05 |
| RIC/NMA | 235 | 2.01 | 1.47-2.74 | <.001 |
| aGVHD, grade 2-4 | ||||
| Main effect | ||||
| Haploidentical HCT | 376 | Reference | ||
| UCB HCT | 285 | 1.83 | 1.46-2.30 | <.001 |
| aGVHD, grade 3-4 | ||||
| Main effect | ||||
| Haploidentical HCT | 376 | Reference | ||
| UCB HCT | 285 | 1.97 | 1.35-2.88 | <.001 |
| cGVHD | ||||
| Main effect | ||||
| Haploidentical HCT | 393 | Reference | ||
| UCB HCT | 297 | 1.13 | 0.86-1.47 | .38 |
| Conditioning regimen | ||||
| MAC-TBI | 375 | Reference | ||
| MAC-chemotherapy | 71 | 1.11 | 0.72-1.72 | .64 |
| RIC/NMA | 243 | 0.65 | 0.49-0.87 | .003 |
| HCT-CI | .05 | |||
| 0 | 169 | Reference | ||
| 1 | 98 | 0.60 | 0.39-0.92 | .02 |
| 2 | 105 | 0.91 | 0.63-1.31 | .60 |
| 3+ | 317 | 0.68 | 0.50-0.91 | .01 |
| Covariate . | No. . | HR . | 95% Confidence interval . | P . |
|---|---|---|---|---|
| OS | ||||
| UCB HCT vs haploidentical HCT (mo) | ||||
| ≤18 | 1.93 | 1.45-2.56 | <.001 | |
| >18 | 0.68 | 0.38-1.21 | .19 | |
| Remission status | ||||
| CR1 | 481 | Reference | ||
| CR2+ | 217 | 1.62 | 1.27-2.07 | <.001 |
| Karnofsky performance status (%) | ||||
| <90 | 259 | Reference | ||
| ≥90 | 429 | 0.81 | 0.64-1.04 | .10 |
| Conditioning regimen | ||||
| MAC-TBI | 380 | Reference | ||
| MAC-chemotherapy | 74 | 2.14 | 1.45-3.14 | <.001 |
| RIC/NMA | 243 | 1.22 | 0.93-1.59 | .15 |
| LFS | ||||
| UCB HCT vs haploidentical HCT (mo) | ||||
| ≤18 | 1.40 | 1.09-1.79 | .007 | |
| >18 | 0.58 | 0.31-1.07 | .08 | |
| Remission status | ||||
| CR1 | 469 | Reference | ||
| CR2+ | 203 | 1.59 | 1.27-1.99 | <.001 |
| Race/ethnicity | ||||
| White Hispanic | 144 | Reference | ||
| White non-Hispanic | 310 | 0.86 | 0.65-1.13 | .27 |
| Black | 83 | 1.33 | 0.93-1.89 | .12 |
| Asian | 41 | 0.55 | 0.31-0.97 | .04 |
| Other/not specified | 94 | 0.94 | 0.65-1.36 | .74 |
| Conditioning regimen | ||||
| MAC-TBI | 364 | Reference | ||
| MAC-chemotherapy | 72 | 1.77 | 1.23-2.55 | .002 |
| RIC/NMA | 235 | 1.51 | 1.19-1.91 | <.001 |
| NRM | ||||
| Main effect | ||||
| Haploidentical HCT | 381 | Reference | ||
| UCB HCT | 291 | 2.08 | 1.45-2.99 | <.001 |
| Karnofsky performance status (%) | ||||
| <90 | 247 | Reference | ||
| ≥90 | 416 | 0.65 | 0.46-0.90 | .01 |
| Conditioning regimen | ||||
| MAC-TBI | 364 | Reference | ||
| MAC-chemotherapy | 72 | 1.96 | 1.16-3.32 | .01 |
| RIC/NMA | 235 | 0.88 | 0.59-1.29 | .51 |
| Relapse | ||||
| Main effect | ||||
| Haploidentical HCT | 381 | Reference | ||
| UCB HCT | 291 | 0.83 | 0.60-1.13 | .23 |
| Remission status | ||||
| CR1 | 469 | Reference | ||
| CR2+ | 203 | 1.88 | 1.40-2.53 | <.001 |
| Race/ethnicity | ||||
| White Hispanic | 144 | Reference | ||
| White non-Hispanic | 310 | 0.99 | 0.68-1.45 | .98 |
| Black | 83 | 1.51 | 0.95-2.39 | .08 |
| Asian | 41 | 0.55 | 0.26-1.19 | .13 |
| Other/not specified | 94 | 0.73 | 0.43-1.25 | .25 |
| Conditioning regimen | ||||
| MAC-TBI | 364 | Reference | ||
| MAC-chemotherapy | 72 | 1.64 | 0.99-2.71 | .05 |
| RIC/NMA | 235 | 2.01 | 1.47-2.74 | <.001 |
| aGVHD, grade 2-4 | ||||
| Main effect | ||||
| Haploidentical HCT | 376 | Reference | ||
| UCB HCT | 285 | 1.83 | 1.46-2.30 | <.001 |
| aGVHD, grade 3-4 | ||||
| Main effect | ||||
| Haploidentical HCT | 376 | Reference | ||
| UCB HCT | 285 | 1.97 | 1.35-2.88 | <.001 |
| cGVHD | ||||
| Main effect | ||||
| Haploidentical HCT | 393 | Reference | ||
| UCB HCT | 297 | 1.13 | 0.86-1.47 | .38 |
| Conditioning regimen | ||||
| MAC-TBI | 375 | Reference | ||
| MAC-chemotherapy | 71 | 1.11 | 0.72-1.72 | .64 |
| RIC/NMA | 243 | 0.65 | 0.49-0.87 | .003 |
| HCT-CI | .05 | |||
| 0 | 169 | Reference | ||
| 1 | 98 | 0.60 | 0.39-0.92 | .02 |
| 2 | 105 | 0.91 | 0.63-1.31 | .60 |
| 3+ | 317 | 0.68 | 0.50-0.91 | .01 |